Carfilzomib cải thiện đáng kể thời gian sống không tiến triển ở bệnh nhân có nguy cơ cao trong bệnh lý đa u tủy xương

Pulte, 2011, Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data., Oncologist, 16, 1600, 10.1634/theoncologist.2011-0229 Stewart, 2015, Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma., N Engl J Med, 372, 142, 10.1056/NEJMoa1411321 Dimopoulos, 2015, Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone., Haematologica, 100, 1327, 10.3324/haematol.2014.117077 Avet-Loiseau, 2007, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome., Blood, 109, 3489, 10.1182/blood-2006-08-040410 Avet-Loiseau, 2013, Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience., J Clin Oncol, 31, 2806, 10.1200/JCO.2012.46.2598 Avet-Loiseau, 2015, Impact of cytogenetics on outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide plus low-dose dexamethasone in the FIRST (MM-020) trial [abstract]., Blood, 126, 10.1182/blood.V126.23.730.730 Avet-Loiseau, 2010, Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone., Leukemia, 24, 623, 10.1038/leu.2009.273 Kumar, 2012, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012;26(5):1153]., Leukemia, 26, 149, 10.1038/leu.2011.196 Jakubowiak, 2013, Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study., Leukemia, 27, 2351, 10.1038/leu.2013.152 Klein, 2011, Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone., Cancer, 117, 2136, 10.1002/cncr.25775 Chang, 2007, Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma., Leuk Res, 31, 779, 10.1016/j.leukres.2006.08.002 Avet-Loiseau, 2010, Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)., J Clin Oncol, 28, 4630, 10.1200/JCO.2010.28.3945 Cavo, 2010, Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study., Lancet, 376, 2075, 10.1016/S0140-6736(10)61424-9 Munshi, 2011, Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2., Blood, 117, 4696, 10.1182/blood-2010-10-300970 Paiva, 2015, New criteria for response assessment: role of minimal residual disease in multiple myeloma., Blood, 125, 3059, 10.1182/blood-2014-11-568907 Landgren, 2016, Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient., Cytometry B Clin Cytom, 90, 14, 10.1002/cyto.b.21273 Sonneveld, 2016, Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group., Blood, 127, 2955, 10.1182/blood-2016-01-631200 Leleu, 2015, Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results., Blood, 125, 1411, 10.1182/blood-2014-11-612069 Lonial, 2015, Elotuzumab therapy for relapsed or refractory multiple myeloma., N Engl J Med, 373, 621, 10.1056/NEJMoa1505654 Moreau, 2016, Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma., N Engl J Med, 374, 1621, 10.1056/NEJMoa1516282 Jakubowiak, 2012, A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma., Blood, 120, 1801, 10.1182/blood-2012-04-422683 Korde, 2015, Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma., JAMA Oncol, 1, 746, 10.1001/jamaoncol.2015.2010